Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Idasanutlin Tablet Variants in Solid Tumors
NCT03362723Phase 1Completed
- Sponsor
- Roche
- Start
- Nov 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of idasanutlin in solid tumor (5 arms), sponsored by Roche. Primary endpoints: Area Under the Curve of Idasanutlin at Day 29 and Maximum Observed Plasma Concentration of Idasanutlin at Day 29. Started Nov 2017; status: completed.
02
Drugs
idasanutlin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03362723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362723.